Skip to main
  1. Stocks
  2. GRAIL Inc
  3. Forecast
GRAL

GRAIL Inc (GRAL) Stock Forecast & Price Target

GRAIL Inc (GRAL) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 10%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

GRAIL is positioned for a constructive fundamental re-rating because Galleri has unusually strong clinical validation, including 99.6% specificity, over 90% Cancer Signal Origin accuracy, a 60% positive-predictive value in PATHFINDER 2, and a 14% reduction in Stage IV diagnoses in NHS-Galleri. The company’s investment case is further strengthened by a large, underpenetrated market opportunity of more than 100 million annual tests in the U.S. at the broadest level, plus potential international expansion and use in nontraditional channels such as concierge medicine, self-insured employers, and telehealth. With FDA approval viewed as increasingly likely and a formal Medicare reimbursement pathway established in February 2026, GRAIL’s extensive dataset and leadership in MCED could support durable long-term adoption and revenue acceleration.

Bears say

GRAIL is burdened by a weak pre-reimbursement commercial ramp, with Q3 screening revenue of about $37.3M and volume near 56,400 missing expectations, while management cut full-year 2026 Galleri screening revenue growth guidance to 17–21% from 22–32%. The company also faces shrinking economics, as adjusted gross margin fell to 42% from 55% a year ago, with a royalty-adjusted level of roughly 35%, and the resumption of the ~7% Illumina royalty in 2027 could further pressure margins if volume growth lags. Beyond these misses, cash-pay demand appears structurally limited by high pricing and weak conversion, and until FDA approval and later reimbursement arrive, the business likely remains trapped in a capital-intensive, cash-burning model with muted visibility on durable scale.

GRAIL Inc (GRAL) has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 10% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRAIL Inc and is not a guaranteed prediction by Public.com or investment advice.

GRAIL Inc (GRAL) Analyst Forecast & Price Prediction

Get the latest GRAIL Inc (GRAL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRAIL Inc (GRAL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRAIL Inc (GRAL) Forecast

Analysts have given GRAIL Inc (GRAL) a Buy based on their latest research and market trends.

According to 10 analysts, GRAIL Inc (GRAL) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $128.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $128.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRAIL Inc (GRAL)


GRAIL Inc (GRAL) Analyst Forecast & Price Prediction

Get the latest GRAIL Inc (GRAL) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in GRAIL Inc (GRAL)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover GRAL stock data and trends